SSRI differntiation: Pharmacology and pharmacokinetics

Human Psychopharmacology: Clinical and Experimental

Volumn 10, Issue 3 S, 1995, Pages S149-S158

  Leonard, B E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

depression; pharmacokinetics; pharmacology; selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DRUG METABOLISM; HUMAN; NEUROTRANSMISSION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0029157647     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.470100903     Document Type: Article

References (57)

1. Steady‐state plasma levels of nortriptyline in twins: influences of genetic factors of drug therapy
2. The efficacy of selective serotonin reuptake inhibitors in depression — a meta‐analysis of studies against tricyclic antidepressants
3. Epidemiology of depression
4. Fluoxetine kinetics and protein binding in normal and impaired renal function
5. 5‐Hydroxyindole acetic acid in cerebrospinal fluid — a biochemical suicide predictor?
6. An interaction of sertraline and desipramine
7. Correction
8. The pharmacokinetics of paroxetine in the elderly
9. Fluoxetine compared with imipramine in the treatment of inpatient depression
10. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness
11. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
12. Clinical pharmacology and pharmacokinetics of fluoxetine: a review
13. Recent developments in hepatic drug metabolism of newer antidepressants
14. Clinical and experimental studies on fluoxetine: effects on serotonin uptake
15. Decreased beta adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine
16. Serotonin receptor sub‐types: implications for psychopharmacology
17. Serotonin function and the mechanism of antidepressant action
18. Modification of serotonergic neuronal properties by long‐term treatment with serotonin re‐uptake blockers
19. Pharmacogenetics of the selective serotonin reuptake inhibitors
20. Pharmacokinetics and drug metabolism of newer antidepressant agents
21. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects
22. The pharmacokinetics of paroxetine in renal impairment
23. Paroxetine in the treatment of severe melancholic depression
24. Double‐blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder
25. A placebo‐controlled in‐patient comparison of fluvoxamine maleate and imipramine in major depression
26. Kinetics of citalopram in elderly patients
27. Basic advances in serotonin pharmacology
28. Pharmacokinetics of second generation antidepressants: fluoxetine
29. Peripheral adrenoceptors and serotonin receptors in depression
30. A pharmacokinetic dose titration study in adult and elderly depressed patients
31. Comparative pharmacology of selective serotonin reuptake inhibitors
32. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
33. Excretion of fluoxetine in human breast milk
34. Paroxetine: a pharmacological review
35. A review of metabolism and pharmacokinetics of paroxetine in man
36. The cost of depression
37. Modelling the cost‐effectiveness of the prophylactic use of selective serotonin reuptake inhibitors in the treatment of depression
38. Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of beta adrenoceptors in rat brain
39. Antidepressants: current concepts of mode of action
40. Pharmacological difference of serotonin reuptake inhibitors — possible clinical relevance
41. The comparative pharmacology of new antidepressants
42. Effect of antidepressants on specific neurotransmitters: are such effects relevant to their therapeutic action?
43. Paroxetine: pharmacokinetics, tolerance and depletion of blood 5HT in man
44. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names and nomenclature
45. Fluoxetine — a clinical and research update. Severity of depression and response to fluoxetine
46. Platelet serotonin 2 receptor binding sites in depression and suicide
47. Sustained plasma concentrations of fluoxetine and/or norfluoxetine 4 and 8 weeks after fluoxetine discontinuation
48. Clinical data on the role of serotonin in the mechanism of action of antidepressant drugs
49. cAMP dependent binding proteins and endogenous phosphorylation after antidepressant treatment
50. The relationship between paroxetine and spartine oxidative polymorphism
51. Toxic reaction following the combined administration of fluoxetine and L‐tyrptophan: 5 case reports
52. Danger of MAOI therapy after fluoxetine withdrawal
53. Tricyclic antidepressants: plasma levels after fluoxetine addition
54. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
55. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single dose administration
56. Fluoxetine — effective in the long term treatment of depression
57. Excretion of fluvoxamine in breast milk